Bottom line
NVOH vs SCHF: the short answer
NVOH (Novo Nordisk A/S (B Shares) ADRhedged) and SCHF (Schwab International Equity ETF) are both etfs.
But SCHF is far broader, holding 1,479 positions to 3 for NVOH, so beyond the top names it adds exposure NVOH doesn't have.
SCHF is cheaper at 0.03% vs 0.19% — a difference of $16 a year per $10,000 invested.
Updated Nov 19, 2026
NVOH vs SCHF side by side
| NVOH | SCHF | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | DWS (Xtrackers) | Schwab |
| Category | International Stock | International Stock |
| Expense ratio | 0.19% | 0.03% |
| Annual cost per $10k | $19 | $3 |
| 10-yr cost on $10k (prospectus) | $243 | $39 |
| Max front load | None | None |
| 12b-1 fee | 0% | — |
| 1-yr return | — | +3.5% |
| 5-yr return (annualized) | — | +5.0% |
| 10-yr return (annualized) | — | +5.4% |
| Best quarter | — | +17.0% |
| Worst quarter | — | −23.1% |
| Net assets (fund) | $4.2M | $66.5B |
| Number of holdings | 3 | 1,479 |
| Portfolio turnover | % | 4% |
| Returns as of | — | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
NVOH and SCHF share none of their top holdings.
NVOH top 10
- Novo Nordisk A/s — 96.87%
- Dreyfus Trsry Securities — 2.79%
- Canadian Imperial Bank Of Commerce — -0.08%
SCHF top 10
- Samsung Electronics Co Ltd — 3.32%
- SK hynix Inc — 2.81%
- ASML Holding NV — 2.10%
- HSBC Holdings PLC — 1.08%
- Roche Holding AG — 0.99%
- Novartis AG — 0.97%
- AstraZeneca PLC — 0.93%
- Royal Bank of Canada — 0.90%
- Nestle SA — 0.88%
- Shell PLC — 0.80%
FAQ
What is the difference between NVOH and SCHF?
NVOH (Novo Nordisk A/S (B Shares) ADRhedged) and SCHF (Schwab International Equity ETF) are both etfs. But SCHF is far broader, holding 1,479 positions to 3 for NVOH, so beyond the top names it adds exposure NVOH doesn't have.
Which is cheaper, NVOH or SCHF?
SCHF has the lower expense ratio (0.03%).
Should I own both NVOH and SCHF?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.